Tech Company Financing Transactions
NGM Biopharmaceuticals Funding Round
NGM Biopharmaceuticals closed a $106 million Series E investment round on 3/26/2015. Investors included private investors.
Transaction Overview
Company Name
Announced On
3/26/2015
Transaction Type
Venture Equity
Amount
$105,999,996
Round
Series E
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
333 Oyster Point Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
NGM Biopharmaceuticals (Nasdaq: NGM) is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
William Rieflin
Chief Executive Officer
David Woodhouse
Chief Medical Officer
Alex DePaoli
Chief Scientific Officer
Jin-Long Chen
Vice President
Wenyan Shen
VP - R & D
Hui Tian
Browse more venture capital transactions:
Prev: 3/26/2015: aPriori Technologies venture capital transaction
Next: 3/26/2015: Gelesis venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs